【技术产业】Catch of the Day: PowerLab Systems Measure
Phylonix, a contract research organization headquartered in Cambridge, MA, develops and markets in vivo zebrafish assays for therapeutic drug screening for research and preclinical studies. The zebrafish is extremely cost-effective compared to larger animal models, and its embryo is already established as a powerful model for studying genetics and developmental biology.
Recently, articles validating adult zebrafish as a model for researching drug-induced QT prolongation have appeared in Circulation and AJP Heart and Circulatory Physiology. Zebrafish and human heart electrophysiological properties are comparable, and ECG patterns, including the PR interval, QRS complex and QT interval, are similar.
QT Prolongation and Pharma Research
According to Patricia McGrath, Phylonix President and CEO, “We decided to get into this area because we could see that the pharmaceutical industry was being mandated to do QT prolongation testing for all their drugs, so if we could get the model to catch on, we hoped we’d catch some customers!”
Phylonix researchers add drugs to the water in the zebrafish’s recording chamber. The ECG signal is acquired using needle electrodes connected to an ADInstruments’ Octal Bio Amp, and PowerLab 8/30 data acquisition unit. The data is recorded and displayed using Chart software. Phylonix electrophysiologist Dr Demian Park has worked closely with ADInstruments staff to optimize their recordings.
Speeding Up Research Outcomes
The ECG Analysis Module has accelerated Phylonix’s data analysis processes. It automatically detects, analyzes and extracts signal parameters, including the QT interval, in real time. As Phylonix’s recordings are extremely long, Dr Park considers this software “really necessary” for research productivity.
screen.width-333)this.width=screen.width-333" width=250 height=193 title="Click to view full phylsetup2.jpg (250 X 193)" border=0 align=absmiddle> [标签:content1][标签:content2]
作者:admin@医学,生命科学 2011-09-19 05:12